GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Senior appointment

30 Nov 2007 07:11

ViaLogy PLC30 November 2007 VIALOGY PLC APPOINTS HEAD OF SALES & MARKETING London, November 30, 2007 -- ViaLogy PLC (AIM: VIY), a leading innovator ofnetwork-centric, real time signal processing platforms for sensor applications,today announced the appointment of Mr. Robert Kern as Vice President, Sales andMarketing for its wholly-owned American subsidiary company, ViaLogy LLC ('ViaLogy'), of Pasadena, California. This senior appointment reflects the transition of the Company's activities fromresearch and development to the commercialisation of its products. Investmentis being made to establish and develop a strong sales and marketing team tosupport the roll-out of ViaLogy's products, initially SPMTM - Sensor PolicyManager, MicroSPMTM and MPEX Electronic EyeTM. Bob Kern joins ViaLogy from the Science Applications International Corporation(SAIC), a global systems integrator and technical services company, where he wasthe Vice President and UK Strategic Account Manager. Previously, he had seniorbusiness development responsibility for SAIC's Defense Intelligence and Securitybusiness and also ran an SAIC business in Europe with several hundred employeesin seven countries. Mr. Kern has also held senior sales and marketing positionswith Silicon Graphics, Sun Microsystems, and Autometric in the intelligence andsecurity business, serving both commercial and government markets. During adistinguished career as a US Air Force Officer, he led efforts to develop fieldintelligence and integrated security systems and architectures for battlespacemanagement. Commenting on his new position, Bob Kern said: "I am very excited by ViaLogy's potential, its technology and value proposition.I look forward to developing our sales channels and partnerships with systemintegrators to incorporate our sensor policy management software and hardwareproducts, which are designed for safety, integrated security, surveillance andbusiness continuity applications." ViaLogy's CEO, Robert W. Dean, welcomed Bob Kern as the company's newest seniorexecutive, saying: "Bob brings to ViaLogy a deep understanding of our customer and market base, andan on-the-ground appreciation of how ViaLogy's unique technologies will play infuture government and commercial integrated security solutions. "Today, in cooperation with a number of global blue-chip companies we aresupporting multiple sensor integration field trials. Bob's internationalexperience will be key in driving our sales growth." For further information please contact: ViaLogyRobert W Dean, President & CEO - US +1 626-296-6337Terry Bond, Chairman - UK & Europe +44 (0)20 2869 7014 Redleaf CommunicationsEmma Kane / Samantha Robbins +44 (0)20 7822 0200 About ViaLogy: Network Centric Signal Processing. ViaLogy is a leading innovator of network-centric, real-time signal processingplatforms for sensor applications. ViaLogy is currently deploying and designingcomputational systems, powered by its patented technologies, for applications inlife sciences, public safety and security, surveillance, defense andgeoseismology. Vialogy focuses on market driven problems where automation,timeliness, quality and reliability of information processing are essential.ViaLogy's core competency incorporates rapidly and accurately detecting weaksignals buried in high noise background and clutter. This technology can beemployed to solve problems involving sensor integration and information overloadchallenges involving video, telephony and control sensors, as well as forenhancement of numerous signal processing applications. For more information,visit our website at www.vialogy.com. Except for statements of historical fact, the information presented hereinconstitutes forward-looking statements within the meaning of the PrivateSecurities Litigation Reform Act of 1995. Such forward-looking statementsinvolve known and unknown risks, uncertainties and other factors which may causethe actual results, performance or achievements of the company to be materiallydifferent from any future results, performance or achievements expressed orimplied. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
7th Feb 20177:00 amRNSSouthern Europe Business Update
10th Jan 20173:33 pmRNSResult of General Meeting
10th Jan 20177:15 amRNSHardman Research: Yourgene improves growth
21st Dec 20164:00 pmRNSPosting of Circular
21st Dec 20167:00 amRNSHalf year results
21st Dec 20167:00 amRNSConditional Acquisition of Yourgene Bioscience
21st Nov 20167:00 amRNSPremaitha establishes first service lab in Asia
31st Oct 20167:00 amRNSPremaitha welcomes UK Govt. decision on NIPT
27th Oct 20164:10 pmRNSResult of AGM
27th Oct 20167:00 amRNSAGM Statement
21st Oct 20167:00 amRNSGrant of Options
3rd Oct 20167:15 amRNSHardman Research: Excellent first year for IONA®
30th Sep 20163:38 pmRNSNotice of AGM
30th Sep 20167:00 amRNSFinal Results
23rd Sep 201610:42 amRNSHolding(s) in Company
23rd Sep 20168:50 amRNSNotice of results & appointment of broker
23rd Sep 20168:50 amRNSInvestment agreement extension with Thermo Fisher
8th Sep 20169:08 amRNSDirectorate Change
6th Jul 20167:00 amRNSDirectorate Change
4th Jul 20167:00 amRNSProgress on anti-trust objections to litigation
22nd Jun 20167:00 amRNSAdoption of Financial Reporting Standard (FRS) 101
22nd Apr 201610:45 amRNSUpdate on competitor patent litigation
20th Apr 201611:14 amRNSHardman Research: IONA sales & litigation update
20th Apr 20167:00 amRNSPatent Litigation Rescheduled
18th Apr 20161:13 pmRNSHardman & Co Issues Research Report
18th Apr 20161:03 pmRNSHardman & Co Issues Research Report
14th Apr 20167:00 amRNSHolding(s) in Company
13th Apr 20169:52 amRNSHolding(s) in Company
13th Apr 20167:00 amRNSHoldings in Company, Director's Shareholding
11th Apr 20167:00 amRNSTrading Update
29th Mar 20167:00 amRNSPremaitha announces tenth customer laboratory
21st Mar 20167:00 amRNSDistribution Agreements in the Middle East
9th Mar 20165:21 pmRNSHolding in Company, Directors' Dealing Replacement
9th Mar 20163:33 pmRNSHolding in Company, Directors' Dealings
9th Mar 20167:00 amRNSDistribution Agreement with GeNext - Russia
7th Mar 20167:00 amRNSAppointment of Joint Broker
3rd Feb 20167:00 amRNSPremaitha partners with Visional Medical in India
2nd Feb 20167:00 amRNSPremaitha partners with Leeds Hospitals NHS Trust
28th Jan 20167:00 amRNSHardman & Co Research Report: IONA®-Up and running
27th Jan 20167:00 amRNSTwo new customers signed for clinical lab service
26th Jan 20162:29 pmRNSUpdate on UK Litigation Timing
15th Jan 20167:00 amRNSPremaitha welcomes NSC recommendation on NIPT
8th Jan 201612:40 pmRNSUpdate on competitor patent litigation
18th Dec 20157:00 amRNSDirector/PDMR Shareholding
16th Dec 20155:53 pmRNSHolding(s) in Company
15th Dec 20157:00 amRNSHardman Issues Research Report
14th Dec 20157:00 amRNSInvestment Agreement with Thermo Fisher Scientific
14th Dec 20157:00 amRNSHalf Yearly Report
11th Dec 20157:00 amRNSNotice of Half Year Results
2nd Dec 20157:00 amRNSFirst IONA® testing service in France at LaboSud

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.